title: [Autoimmune hemolytic anemia].
abstract: Diagnosis of autoimmune hemolytic anemia (AIHA) requires both serologic evidence of an autoantibody and hemolysis. Based on the characteristic temperature reactivity of the autoantibody to red cell membranes, AIHA is classified into warm AIHA or cold AIHA (cold agglutinin disease and paroxysmal cold hemoglobinuria). Sensitized RBCs are destructed by intravascular and/or extravascular hemolysis. On the basis of etiology, AIHA are classified as idiopathic or secondary. The common cause of secondary AIHA is lymphoproliferative disorders, autoimmune diseases, and infections. The first line therapy of patients with warm AIHA is glucocorticoids and primary treatment for cold AIHA is avoiding cold exposure. The other standard treatments include splenectomy and immunosuppressive drugs. Recently, rituximab, a monoclonal anti-CD20 antibody, has been used in refractory AIHA with excellent responses.
authors.affiliation: Blood Transfusion Service, University Hospital, Faculty of Medicine, Gunma University.
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Karasawa
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D001327:Autoimmune Diseases / Q000150:complications; D003298:Coombs Test; D004910:Erythrocyte Membrane; D005938:Glucocorticoids / Q000009:adverse effects; D006457:Hemoglobinuria, Paroxysmal; D006461:Hemolysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000150:complications; D000069283:Rituximab; D013156:Splenectomy; D013696:Temperature
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D000069283:Rituximab